ASCO 2024 starts today - Check out our ASCO investor tool
📣 Big day Today for ASCO 2024
The American Society of Clinical Oncology (ASCO) annual meeting is always a significant event in the biopharma world, offering a platform for the latest breakthroughs and insights in cancer research.
Our team has been diligently creating ASCO investor tools to help navigate the plethora of clinical trial data. We’ve been scouring press releases for smid-cap readouts at ASCO.
To date, we have identified 77 smid-cap clinical trial readouts at ASCO 2024 (see Figs below 📸).
To find biopharma smid-caps that are most likely to be ASCO movers 📈
FIG. 1. Phase 1 data readouts.
FIG. 2. Phase 1/2 data readouts.
FIG. 3. Phase 2/3 data readouts.
Abstract Winners and Losers
Last Friday’s abstract release had a significant impact on several biopharma stocks. Here are the top gainers and biggest losers:
Top Gainers:
MRUS: +38.72%
AGEN: +9.64%
BLRX: +9.08%
COGT: +8.28%
CGEM: +6.18%
Biggest Losers:
VSTM: -62.52%
SNSE: -51.38%
KRON: -21.13%
HOOK: -17.68%
CADL: -12.63%
Check out the image below for more details 📸
FIG. 4. ASCO 2024 Abstract Winners and Losers. Based on stock moves on 5/24/24.
Here are the links to our ASCO free tools:
Get access to our full ASCO 2024 investor tools ⛏️
Become an Elite subscriber today!
🚨 50% ASCO special ends soon 🚨 👉 CLICK HERE to sign up today!
---------------------------------
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 05/31/24 JR & EJV